Skip to main content

Table 1 Demographic data, stage, primary tumor histology and type of first CPI treatment

From: Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

 

All patients

(n = 428)

Ongoing CR

(n = 77)

Died < 6 months

(n = 69)

No local therapy**

(n = 230)

NED or NPRD

(n = 52)

Median age (IQR)

65 (55 – 74)

68 (55 – 75)

65 (58 – 74)

64 (55 – 74)

61 (54 – 70)

Gender

63% male

68% male

67% male

61% male

62% male

Stage before CPI

 Stage M1a (%)

 Stage M1b (%)

 Stage M1c (%)

 Stage M1d (%)

99 (23%)

90 (21%)

152 (36%)

87 (20%)

22 (29%)

21 (27%)

31 (40%)

3 (4%)

11 (16%)

8 (12%)

36 (52%)

14 (20%)

55 (24%)

53 (23%)

69 (30%)

53 (23%)

11 (21%)

8 (15%)

16 (31%)

17 (33%)

Sun-shielded*

93 (22%)

5 (6%)

19 (28%)

54 (23%)

15 (29%)

1st Therapy (%)

 CTLA4

 PD1 or PDL1

 CTLA4 + PD1

124 (29%)

129 (30%)

175 (41%)

11 (14%)

23 (30%)

43 (56%)

28 (41%)

23 (33%)

18 (26%)

69 (30%)

71 (31%)

90 (39%)

16 (31%)

12 (23%)

24 (46%)

  1. Abbreviations: CR = complete response; IQR = interquartile range; NED = no evidence of disease; NPRD = non-progressive residual disease
  2. Stage M1a = distant metastases to skin or lymph nodes. Stage M1b = metastases to lung with or without M1a metastases. Stage M1c = metastases to visceral sites with or without M1a or M1b. Stage M1d = metastases to CNS with or without extra-cranial metastasis [20]
  3. *Sun-shielded melanomas include mucosal, ocular, perineal, and acral lentiginous
  4. **Some patients had procedures that did not meet inclusion criteria